Chimeric Therapeutics Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	3.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Oct 13

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Feb 23

We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Oct 20

AMMINISTRATORE DELEGATO

Chimeric Therapeutics non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Hopper	Founder & Executive Chairman	4.8yrs	AU$301.98k	10.49% A$ 855.0k
Phillip Hains	CFO, Joint Company Secretary & Director	4.1yrs	Nessun dato	1.14% A$ 92.9k
Rebecca McQualter	Chief Operating Officer	less than a year	AU$453.86k	Nessun dato
Jason Litten	Chief Medical Officer	2.3yrs	AU$1.16m	Nessun dato
Kelly Thornburg	VP & Head of Quality	2.8yrs	Nessun dato	Nessun dato
Nathan Jong	Joint Company Secretary	4.1yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di CHM è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Hopper	Founder & Executive Chairman	4.8yrs	AU$301.98k	10.49% A$ 855.0k
Phillip Hains	CFO, Joint Company Secretary & Director	1.3yrs	Nessun dato	1.14% A$ 92.9k
Larry Couture	Member of Glioblastoma Expert Advisory Board	no data	Nessun dato	Nessun dato
Eric Sullivan	Non-Executive Director	1.3yrs	AU$68.78k	Nessun dato
Lesley Russell	Non-Executive Director	4.3yrs	AU$50.00k	0.19% A$ 15.7k
David Maloney	Member of Cellular Immunotherapy Scientific Advisory Board	3.2yrs	Nessun dato	Nessun dato
Nader Sanai	Member of Glioblastoma Expert Advisory Board	no data	Nessun dato	Nessun dato
Yvonne Chen	Member of Glioblastoma Expert Advisory Board	3.8yrs	Nessun dato	Nessun dato
Christine Brown	Chairman of Glioblastoma Expert Advisory Board	no data	Nessun dato	1.34% A$ 109.5k
Yi Lin	Member of Cellular Immunotherapy Scientific Advisory Board	3.3yrs	Nessun dato	Nessun dato
Eric Smith	Member of Cellular Immunotherapy Scientific Advisory Board	3.2yrs	Nessun dato	Nessun dato
Michael Bishop	Member of Cellular Immunotherapy Scientific Advisory Board	3.2yrs	Nessun dato	Nessun dato

3.2yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CHM sono considerati esperti (durata media dell'incarico 3.2 anni).

Chimeric Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023

Chimeric Therapeutics Limited Announces Board Changes

Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director

Chimeric Therapeutics Limited Announces Board Changes

No independent directors

Recent updates

Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024

New major risk - Share price stability

New major risk - Market cap size

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.

New major risk - Shareholder dilution

Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101

New minor risk - Share price stability

Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023

Price target decreased by 14% to AU$0.60

New minor risk - Financial data availability

Chimeric Therapeutics Limited Announces Board Changes

Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director

Chimeric Therapeutics Limited Announces Board Changes

Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical Trial

Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 Trial

Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib Trial

Chimeric Therapeutics Limited Completes Dosing in Third Cohort of CHM 1101 (CLTX CAR T) Trial

Price target decreased to AU$0.71

No independent directors

Chimeric Therapeutics Limited, Annual General Meeting, Nov 15, 2022

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Chimeric Therapeutics Limited Appoints Jason B. Litten as Chief Medical Officer

Chimeric Therapeutics Announces First Ever Phase 1B Trial of NK Cells with IL-2 & Vactosertib

Chimeric Therapeutics Announces the Completion of Manufacturing and Quality Release for CHM 1101 (CLTX CAR T) Viral Vector, a Key Milestone in its Development

No independent directors

Here's Why We're Watching Chimeric Therapeutics' (ASX:CHM) Cash Burn Situation

Chimeric Therapeutics Limited Announces Encouraging Data from 2Nd Dose Cohort in CLTX CAR T trial

Chimeric Therapeutics Limited Successful Completion of 2nd Dose Cohort in CLTX CAR T Trial

Executive Chairman recently bought AU$98k worth of stock

Chimeric Therapeutics Limited Highlights Key Additional Data Released with the Final Presentation of Two CLTX Car T Abstracts At the Society for Neuro-Oncology 26th Annual Scientific Meeting

We Think Chimeric Therapeutics (ASX:CHM) Needs To Drive Business Growth Carefully

Non-Executive Director recently bought AU$166k worth of stock

Chimeric Therapeutics Announces Initiation of Second Dose Cohort

Chimeric Therapeutics Limited Announces Successful Completion of Dosing in First Patient Cohort

Chimeric Therapeutics Appoints Cindy Elkins as Non-Executive Director

Chimeric Therapeutics Limited Appoints Dr. Yvonne Chen to Scientific Advisory Board

Chimeric Therapeutics Limited Appoints Paul Hopper as Director

Chimeric Therapeutics Limited has completed an IPO in the amount of AUD 35 million.

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media